{"id":2188,"date":"2025-06-26T07:07:39","date_gmt":"2025-06-26T07:07:39","guid":{"rendered":"https:\/\/ncdconnect.org\/?p=2188"},"modified":"2025-07-08T08:24:57","modified_gmt":"2025-07-08T08:24:57","slug":"ncdconnect-act-for-children-paediatric-cancer-gap-news","status":"publish","type":"post","link":"https:\/\/ncdconnect.org\/en\/ncdconnect-act-for-children-paediatric-cancer-gap-news\/","title":{"rendered":"NCDconnect & ACT for Children: Closing the Paediatric Cancer Gap"},"content":{"rendered":"\n

In many low- and middle-income countries (LMICs), a childhood cancer diagnosis often comes with limited access to timely treatment, essential medicines, and consistent care. That\u2019s why earlier this year, NCDconnect<\/a>\u2014through IDA Foundation<\/a>\u2014joined the Access Cancer Treatment (ACT) for Children<\/a><\/strong> initiative, a global collaboration focused on bridging the care and access gap for pediatric cancer patients in underserved regions.<\/p>\n\n\n\n

<\/p>\n\n\n\n

\"\"
A paediatric oncology patient in the Ay\u00fadame a Vivir hospital in Guatemala.<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

ACT for Children unites Childhood Cancer International<\/a> (CCI)<\/strong>, the International Society of Paediatric Oncology<\/a> (SIOP)<\/strong>, Resonance<\/a><\/strong>, Servier<\/a><\/strong>, World Child Cancer<\/a><\/strong>, and IDA Foundation\/NCDconnect<\/strong>\u2014working in close collaboration with the Union for International Cancer Control (UICC)-led ATOM Coalition<\/a><\/strong>\u2014to strengthen the childhood cancer ecosystem, from medicine access to clinical care and patient support.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Five Countries, $2.8M in Paediatric Cancer Medicines: ACT\u2019s Impact So Far<\/h1>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

\n
\n

Through ACT for Children, $2.8 million worth of high-quality paediatric oncology medicines<\/strong> have been delivered to five hospitals across Asia and Central America<\/strong>, supporting over 1,000 children<\/strong> with acute lymphoblastic leukaemia (ALL).<\/p>\n\n\n\n

This includes the distribution of peg-asparaginase<\/strong>, a critical medicine in the treatment of Acute Lymphoblastic Leukaemia (ALL), provided by Servier and safely delivered by IDA Foundation via NCDconnect\u2019s supply chain ecosystem. The first deliveries were completed in Armenia<\/strong>, El Salvador<\/strong>, Guatemala<\/strong>, Indonesia<\/strong> and Honduras<\/strong> earlier this year (2025).<\/p>\n<\/div>\n\n\n\n

\n
\"\"
Cold chain medicine stored in a medical fridge at Hospital Benjamin<\/em>
Bloom, San Salvador, El Salvador.<\/em><\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n\n\n

Hospitals served include:<\/strong><\/p>\n\n\n\n